DrugPatentWatch Database Preview
Revefenacin - Generic Drug Details
What are the generic sources for revefenacin and what is the scope of freedom to operate?
Revefenacin
is the generic ingredient in one branded drug marketed by Mylan Ireland Ltd and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Revefenacin has seventy patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for revefenacin
| International Patents: | 70 |
| US Patents: | 13 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 21 |
| Clinical Trials: | 11 |
| Patent Applications: | 42 |
| DailyMed Link: | revefenacin at DailyMed |
Recent Clinical Trials for revefenacin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mylan Inc. | Phase 3 |
| Theravance Biopharma | Phase 3 |
| Theravance Biopharma R & D, Inc. | Phase 1/Phase 2 |
Synonyms for revefenacin
| 1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1'-biphenyl)-2-yl)carbamate |
| 1211931-83-7 |
| 864750-70-9 |
| BCP15793 |
| Biphenyl-2-ylcarbamic acid, 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester |
| Carbamic acid, N-(1,1'-biphenyl)-2-yl-, 1-(2-((4-((4-(aminocarbonyl)-1-piperidinyl)methyl)benzoyl)methylamino)ethyl)-4-piperidinyl ester |
| CHEMBL3833319 |
| CS-7743 |
| D10978 |
| DB11855 |
| EX-A1722 |
| G2AE2VE07O |
| GSK-1160724 |
| GSK1160724 |
| HY-15851 |
| Revefenacin (USAN/INN) |
| Revefenacin [INN] |
| Revefenacin [USAN:INN] |
| Revefenacin [WHO-DD] |
| Revefenacin; TD-4208; GSK-1160724 |
| SCHEMBL356480 |
| TD-4208 |
| TD-4208; GSK-1160724;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate |
| UNII-G2AE2VE07O |
US Patents and Regulatory Information for revefenacin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for revefenacin
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 549472 | Start Trial |
| Taiwan | I341836 | Start Trial |
| Mexico | 2012000682 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
